NEURALGIA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Neuralgia Treatment Market, By Drug Type (Anticonvulsants, Antidepressants, Opioids, Non-steroidal anti-inflammatory Drugs (NSAIDs), and Others), By Route of Administration (Oral, Intravenous, Transdermal, and Others), By Severity (Mild, Moderate, and Severe), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In July 2024, Adalvo Limited, a global pharmaceutical company, introduced Pregabalin Extended-Release (ER) tablets in Europe for the treatment of neuropathic pain. This new formulation provides the advantage of less frequent dosing, enhancing patient convenience and adherence to the treatment regimen.
In April 2024, Vertex Pharmaceuticals, a pharmaceutical company, announced advancements in its suzetrigine (VX-548) pain treatment program, targeting neuralgia management
In March 2024, Apollo Hospitals Group introduced the Zap-X Gyroscopic Radiosurgery Platform in Chennai, India offering precise, non-invasive treatment for brain tumors with improved accuracy, fewer side effects, and faster recovery times, enhancing patient outcomes in neurological care
In January 2024, the U.S. FDA approved Neuralace Medical's Axon Therapy, a non-invasive neurostimulation treatment for painful diabetic neuropathy (PDN). The technology uses low-voltage electrical pulses to reduce nerve pain without drugs or invasive procedures.